Targeting the epidermal growth factor receptor: prognostic and clinical implications
Herbst R. Targeting the epidermal growth factor receptor: prognostic and clinical implications. European Journal Of Cancer Supplements 2003, 1: 9-15. DOI: 10.1016/s1359-6349(03)80015-0.Peer-Reviewed Original ResearchEpidermal growth factor receptorGrowth factor receptorEGFR tyrosine kinase inhibitor gefitinibFactor receptorTyrosine kinase inhibitor gefitinibCell lung cancerKinase inhibitor gefitinibPerformance statusClinical responseSkin toxicityPrognostic valueDisease characteristicsLung cancerSurrogate markerClinical trialsNovel anticancer agentsInhibitor gefitinibClinical implicationsGefitinibAntitumour activityBiological markersPromising targetExpression levelsTumorigenic processAnticancer agentsMode of action of docetaxel – a basis for combination with novel anticancer agents
Herbst RS, Khuri FR. Mode of action of docetaxel – a basis for combination with novel anticancer agents. Cancer Treatment Reviews 2003, 29: 407-415. PMID: 12972359, DOI: 10.1016/s0305-7372(03)00097-5.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsApoptosisDocetaxelDrug Resistance, NeoplasmDrug SynergismErbB ReceptorsFemaleFollow-Up StudiesHumansMaleNeoplasmsNeovascularization, PathologicPaclitaxelPharmacogeneticsSurvival AnalysisTaxoidsTreatment OutcomeConceptsPatient populationOptimal treatment strategySpecific patient populationsCertain chemotherapeutic drugsAnticancer agentsOptimal therapySpecific therapyTreatment strategiesNovel agentsClinical investigationNew anticancer agentsNovel anticancer agentsCancer growthDifferent tumorsStimulation pathwayChemotherapeutic drugsInhibitor of mitosisAntitumor activityTumorigenic mechanismsMode of actionAgent combinationsDocetaxelTherapyAgentsDifferent aberrations